EP2629788A4 - Use of human serum albumin to decrease antigenicity of therapeutic proteins - Google Patents

Use of human serum albumin to decrease antigenicity of therapeutic proteins

Info

Publication number: EP2629788A4
Authority: EP; European Patent Office
Prior art keywords: serum albumin; human serum; therapeutic proteins; decrease antigenicity; antigenicity
Prior art date: 2010-10-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP11835285.5A

Other languages

German (de)

French (fr)

Other versions

EP2629788A2 (en

Inventor

Fahar Merchant

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Protox Therapeutics Corp

Original Assignee

Protox Therapeutics Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-10-22

Filing date

2011-10-24

Publication date

2014-03-19

2011-10-24 Application filed by Protox Therapeutics Corp filed Critical Protox Therapeutics Corp

2013-08-28 Publication of EP2629788A2 publication Critical patent/EP2629788A2/en

2014-03-19 Publication of EP2629788A4 publication Critical patent/EP2629788A4/en

Status Withdrawn legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2026—IL-4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A61K38/385—Serum albumin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Inorganic Chemistry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Dermatology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Oil, Petroleum & Natural Gas (AREA)

EP11835285.5A 2010-10-22 2011-10-24 Use of human serum albumin to decrease antigenicity of therapeutic proteins Withdrawn EP2629788A4 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US40605210P	2010-10-22	2010-10-22
PCT/US2011/057530 WO2012054929A2 (en)	2010-10-22	2011-10-24	Use of human serum albumin to decrease antigenicity of therapeutic proteins

Publications (2)

Publication Number	Publication Date
EP2629788A2 EP2629788A2 (en)	2013-08-28
EP2629788A4 true EP2629788A4 (en)	2014-03-19

Family

ID=45975941

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP11835285.5A Withdrawn EP2629788A4 (en)	2010-10-22	2011-10-24	Use of human serum albumin to decrease antigenicity of therapeutic proteins

Country Status (4)

Country	Link
US (1)	US20160354472A1 (en)
EP (1)	EP2629788A4 (en)
AU (1)	AU2011316786A1 (en)
WO (1)	WO2012054929A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2012088446A1 (en)	2010-12-22	2012-06-28	Board Of Trustees Of The Leland Stanford Junior University	Superagonists and antagonists of interleukin-2
US9512194B2 (en)	2012-01-27	2016-12-06	The Board Of Trustees Of The Leland Stanford Junior University	Modified IL-13 polypeptides
CN104619334A (en)	2012-08-09	2015-05-13	利兰斯坦福初级大学董事会	Superkines and synthekines: repurposed cytokines with new and enhanced signaling activities
WO2015042705A1 (en) *	2013-09-24	2015-04-02	Medicenna Biopharma Inc.	Interleukin-4 receptor-binding fusion proteins and uses thereof
WO2015042707A1 (en)	2013-09-24	2015-04-02	Medicenna Therapeutics Pte Ltd	Interleukin-2 fusion proteins and uses thereof
US10150802B2 (en)	2014-04-24	2018-12-11	The Board Of Trustees Of The Leland Stanford Junior University	Superagonists, partial agonists and antagonists of interleukin-2
WO2016115415A1 (en) *	2015-01-16	2016-07-21	The Johns Hopkins University	Albumin-proaerolysin prodrugs
JP2019507732A (en) *	2016-01-27	2019-03-22	ソフィリスバイオ，インコーポレイテッド	Methods for targeted intraprostatic administration of PRX 302 for the treatment of prostate cancer
JP7433051B2 (en)	2017-06-19	2024-02-19	メディシナセラピューティクスインコーポレイテッド	Uses and methods of IL-2 superagonists, agonists, and fusions thereof
US11795235B2 (en)	2017-09-18	2023-10-24	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Immunotoxins with albumin binding domain
US12274735B2 (en)	2017-10-10	2025-04-15	Medicenna Therapeutics Inc.	IL-4-fusion formulations for treatment of central nervous system (CNS) tumors
JP7497340B2 (en)	2018-05-14	2024-06-10	ウェアウルフセラピューティクス，インコーポレイテッド	Activatable interleukin-12 polypeptides and methods of use thereof - Patents.com
CA3100007A1 (en)	2018-05-14	2019-11-21	Werewolf Therapeutics, Inc.	Activatable interleukin-2 polypeptides and methods of use thereof
CN114450022A (en)	2019-05-14	2022-05-06	狼人治疗公司	Separation fraction and method of use thereof
KR20220101147A (en)	2019-11-14	2022-07-19	웨어울프 세라퓨틱스, 인크.	Activatable cytokine polypeptides and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US782476A (en) *	1904-02-02	1905-02-14	Frank L Winters	Removable cover and holder for pass and sales books.
US6946134B1 (en) *	2000-04-12	2005-09-20	Human Genome Sciences, Inc.	Albumin fusion proteins
WO2006133553A1 (en) *	2005-06-14	2006-12-21	Protox Therapeutics Incorporated	Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5635599A (en) *	1994-04-08	1997-06-03	The United States Of America As Represented By The Department Of Health And Human Services	Fusion proteins comprising circularly permuted ligands
US6737511B1 (en) *	1999-08-16	2004-05-18	The United States Of America As Represented By The Department Of Health And Human Services	Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis
DK1567641T3 (en) *	2001-08-24	2012-08-27	Uvic Industry Partnerships Inc	Proaerolysin containing protease activation sequences and methods for use in the treatment of prostate cancer.
EP2352526A1 (en) *	2008-09-19	2011-08-10	Protox Therapeutics Inc.	Treating cancer stem cells using targeted cargo proteins
US20100183545A1 (en) *	2008-10-14	2010-07-22	The United States Of America, As Represented By The Secretary,	Targeted cargo protein combination therapy

2011
- 2011-10-24 EP EP11835285.5A patent/EP2629788A4/en not_active Withdrawn
- 2011-10-24 US US13/280,165 patent/US20160354472A1/en not_active Abandoned
- 2011-10-24 AU AU2011316786A patent/AU2011316786A1/en not_active Abandoned
- 2011-10-24 WO PCT/US2011/057530 patent/WO2012054929A2/en active Application Filing

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US782476A (en) *	1904-02-02	1905-02-14	Frank L Winters	Removable cover and holder for pass and sales books.
US6946134B1 (en) *	2000-04-12	2005-09-20	Human Genome Sciences, Inc.	Albumin fusion proteins
WO2006133553A1 (en) *	2005-06-14	2006-12-21	Protox Therapeutics Incorporated	Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins

Also Published As

Publication number	Publication date
EP2629788A2 (en)	2013-08-28
US20160354472A1 (en)	2016-12-08
WO2012054929A2 (en)	2012-04-26
WO2012054929A3 (en)	2012-08-30
AU2011316786A1 (en)	2013-05-02

Publication	Publication Date	Title
EP2629788A4 (en)	2014-03-19	Use of human serum albumin to decrease antigenicity of therapeutic proteins
IL265707A (en)	2019-05-30	Pharmaceutical compositions comprising human antibodies to pcsk9
IL287381A (en)	2021-12-01	Pharmaceutical preparations of human rpe cells and uses thereof
IL232073A0 (en)	2014-05-28	Recombinant human naglu protein and uses thereof
IL279676A (en)	2021-03-01	Recombinant proteins and their therapeutic uses
HUE053720T2 (en)	2021-07-28	Therapeutic antibodies to ROR-1 protein and methods for their use
EP2874642A4 (en)	2016-07-27	Anti-inflammatory proteins and peptides and methods of preparation and use thereof
IL236738B (en)	2022-04-01	Human antibodies to gfrɑ3 and methods of use thereof
IL235482A0 (en)	2014-12-31	Therapeutic uses of fibroblast growth factor 21 proteins
ZA201307641B (en)	2015-04-29	Human tissue factor antibody and uses thereof
ZA201305266B (en)	2014-09-25	Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
IL223665B (en)	2020-01-30	Human antibodies to human cytomegalovirus (cmv) gb protein
PL2660593T3 (en)	2019-05-31	Determination of levels of immunogenic gluten peptides in human samples
IL229748A0 (en)	2014-01-30	Binding compounds to human ß1-adrenoreceptor (ß1-ar)and their use in the measurement of auto-anti-ßa1-ar antibodies
SI2555790T1 (en)	2016-09-30	THERAPEUTIC USE OF THE ss2-MICROGLOBULIN PROTEIN
HK1187834A (en)	2014-04-17	Cyaa-carried polypeptide(s) and use to induce both therapeutic and prophylactic immune responses
PT3326648T (en)	2021-05-04	Pharmaceutical compositions comprising human antibodies to pcsk9
HK1191660A (en)	2014-08-01	Pharmaceutical compositions comprising human antibodies to pcsk9
HK1194078A (en)	2014-10-10	Human tissue factor antibody and uses thereof
IL228933A0 (en)	2013-12-31	Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic proteins

Legal Events

Date	Code	Title	Description
2013-07-26	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2013-08-28	17P	Request for examination filed	Effective date: 20130412
2013-08-28	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2014-01-29	DAX	Request for extension of the european patent (deleted)
2014-03-19	A4	Supplementary search report drawn up and despatched	Effective date: 20140219
2014-03-19	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 39/395 20060101ALI20140213BHEP Ipc: A61K 38/20 20060101ALI20140213BHEP Ipc: A61K 38/17 20060101ALI20140213BHEP Ipc: A61P 35/00 20060101ALI20140213BHEP Ipc: A61K 38/38 20060101AFI20140213BHEP
2015-02-06	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2015-03-11	18D	Application deemed to be withdrawn	Effective date: 20140918